Last updated on April 2018

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)


Brief description of study

This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on prostate size and related lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH).

Detailed Study Description

This clinical trial is designed as a randomized, placebo-controlled, multi-center phase 2 trial to evaluate the efficacy and safety of OPK-88004 in men with benign prostatic hyperplasia. Eligible subjects will be randomized into one of two OPK-88004 treatment groups or a placebo group after a 4-week screening period. Subjects will have monthly visits over a 16- week treatment period and will be evaluated for the effect of OPK-88004 on prostate volume and safety measures, as well as plasma levels of OPK-88004.

Clinical Study Identifier: NCT03297398

Contact Investigators or Research Sites near you

Start Over

APF Research, LLC

Miami, FL United States
8.31miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.